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The Neurosensory System Controls Keratinocyte Release of Growth and Survival Factor Nerve Growth Factor
One of the major developments in human biology is the
understanding of how release of growth factors and other proteins
can be controlled by both local and systemic signals of many types
and sources: circulating hormones, cytokines released from
lymphocytes and macophages activated by the immune response,
cytokines and growth factors from neighboring cells, and
neuropeptides released by autonomic and sensory nerves. In the
skin, the keratinocytes are a major target of stimulation by
hormones, neuropeptides, cytokines, chemokines, and external
stimuli such as ultraviolet light, heat, and cold, and control a major
part of cutaneous biology through the release of cytokines,
chemokines, growth factors, and other types of in¯ammatory
mediators.
Nerve growth factor (NGF) is detected in the neurons of the
central and peripheral nervous system, and is found in the skin in
keratinocytes, endothelial cells, and Langerhans cells. It is believed
to be an important factor in neuronal maintenance, survival, and
repair in the skin, especially during in¯ammatory reactions and
wound healing. NGF is also an important survival factor for human
melanocytes, and may affect melanocyte survival in segmental
vitiligo and other pigmentary disorders.
In this issue, Burbach et al (p. 1075) report that the neuropeptides
Substance P and Neurokinin A induce transcription of NGF and
secretion of bio-active protein from both human and murine
keratinocytes. They also demonstrate increases in expression of
NGF in murine epidermis exposed to capsaicin, a potent inducer of
substance P release. Considering the mass of keratinocytes and the
extensive sensory nerve network that serves it, one would conclude
that keratinocyte-derived NGF controls innervation in the papillary
dermis and melanocyte survival in the epidermis. Activation of
neuropeptides may control key responses in wound healing and
remodeling of the papillary dermis and dermis, through the
transcription and release of keratinocyte NGF.
Inhibition of Angiogenesis Can Selectively Target Tumor Growth But Spare Wound Healing
Vascular genesis refers to the process of blood vessel formation
during development. Angiogenesis is new vessel formation, in
tissue repair or during tumorgenesis. Angiogenesis is a key factor in
survival of tumors once they progress past a small initial tumor
mass, and inhibition of tumor angiogenesis has been proposed as a
new therapeutiuc approach by Folkman and colleagues.
Angiogenesis is a highly regulated process with both ``on'' and
``off'' controls, intended to ®rst induce new vessel formation in
responses to wounding or other stimuli, and then cause regression
of the new vessels when the stimulus is repaired. The ``off'' signal is
not effectively applied in primary tumors, which ``hijack'' the
angiogenesis process to promote local tumor survival. Angiogenesis
is induced by a family of isoforms of vascular endothelial growth
factor (VEGF) and a corresponding family of receptors, and by the
angiopoeitins and their receptors. In addition, angiogenesis can be
controlled by a family of naturally occurring inhibitors of
angiogenesis: Thrombospondin-1 and ±2, angiostatin (a fragment
of plasminogen), and endostatin (a fragment of collagen XVIII).
Vasostatin is a 180 amino acid NH2-terminal fragment of human
calreticulin that also has potent antiangiogenic activity, and is a
candidate for clinical antiangiogenesis trials.
In this issue, Lange-Asschenfeldt et al (p. 1036) used an in vivo
murine model to simultaneously study the effects of vasostatin on
angiogensis and wound healing. Vasostatin was found to inhibit
both tumor growth and angiogenesis in a CA46 Burkitt Lymphoma
model. Interesting, the rate of wound healing in these vasostatin-
treated animals was not decreased, even though the angiogenic
response in the healing wounds was greatly diminished. These
results support the hypothesis that malignant tumor growth is more
sensitive to inhibition of angiogenesis than is physiologic tissue
repair. These ®ndings support an optimistic view that chronic
antiangiogenic therapy can be used to selectively reverse tumor
vascularity without impairing physiologic tissue repair.
Another paper in this issue examines the effects of endogenous
antiangiogenic protein on melanoma metastasis, and may even
support the view that use of angiogenesis inhibitors is mandatory in
large melanomas from which micrometastases may have already
spread. Judah Folkman has made the observation that surgical
removal of a primary tumor is often followed by increased growth
in pre-existing mico-metastases. He has hypothesized that this
phenomenon is explained by the fact that the primary tumor
secretes large amounts of long-lasting antiangiogenic proteins that
inhibit the growth of early distant micrometastases. He proposes
that the primary tumor also makes large amounts of angiogenic
factors that are locally bound, and short lived, and promote local
tumor angiogensis around the large primary tumor. This hypothesis
is tested by Rofstad et al (p. 1042) in a mouse model with existing
melanoma tumors derived from cell lines that produced large
amounts of the antiangiogenis factor Thrombospondin-1, or a cell
line that did not. Tumors that produced large amounts of TSP-1
greatly reduced the experimental establishment of micrometastases,
either from the primary tumor or from tail-vein injection. This
effect was blocked by simultaneous injection of anbti-TSP-1. A
melanoma line negative for TSP-1 produced neo-vascularized lung
colonies after venous inoculation in mice with pre-existing tumors,
whereas injection of TSP-1 positive cells in mice already bearing
tumors from the same cell lines only produced avascular
microcolonies with elevated apoptotic activity.
This work poses an interesting question: must excision of large
melanomas be accompanied by angiogenic inhibitors like TSP-1 to
replace the angiogenesis inhibitors secreted by the primary tumor
before excision?
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UVA is Necessary for UV-Induced Immune Suppression: Implications for Sunscreen Design
Spongiosis is a prominent histologic feature of in¯ammatory skin
disorders characterized by widening of the intercellular spaces
between keratinocytes accompanied by cellular condensation. In
this issue, Trautmann et al (p. 927) demonstrate that, in eczematous
dermatitis, spongiosis is linked to proteolytic cleavage and
functional inactivation of E-cadherin which occurs as a conse-
quence of keratinocyte apoptosis. Interestingly, keratinocyte
apoptosis and attendant E-cadherin cleavage could be induced in
vitro by activated T lymphocytes and was dependent on Fas/CD95
activation. These results provide tantalizing evidence for immune-
mediated keratinocyte death, executed by activation of death
receptors, as a mechanism for spongiotic changes in the skin.
Two papers in this issue show that UVR suppression of delayed-
type hypersensitivity may depend on the UVA spectrum, using
both specialized light sources and selective sunscreens to show that
this type of immune suppression is induced by UVA (more
speci®cally UVAII) and is blocked by sunscreens containing UVA
blockers.
In this issue, Nghiem et al (p. 1193) report that solar-simulated
radiation applied to immunized mice suppress immunologic
memory and elicitation of DTH reaction. UVA sources (320±
400 nm) were as effective as solar simulator radiation (290±400 nm),
but UVAI sources (340±290 nm) were not effective. The
immunosuppressive effect of UVR was blocked by sunscreens that
blocked UVA. The authors state that ``sunlight-induced suppres-
sion of established immune reactions may serve as a risk factor for
increased susceptibility to infectious agents'', and further illustrate
the potential role for UVA in melanoma induction and suppression
of immune responses to established melanomas.
In another article in this issue, Moyal and Fourtanier (p. 1186)
demonstrated the roles of UVA in inhibiting DTH reactions in
humans. The authors studied established DTH reactions using a
panel of recall antigens to which most individuals react. Using both
solar simulator and natural outdoor sunlight to inhibit DTH
reactions, they showed that this inhibition could be blocked with
sunscreens, but only if they contained highly effective UVA
sunscreens. The authors state that ``the SPF, an indicator of
protection against sunburn, is not an indicator of the protection
against the suppression of the elicitation phase of immune response
induced by repeated UV exposures''. They conclude that
``sunscreens with improved UVA protection have a higher immune
protection factor (IPF)''.
These papers further illustrate the importance of UVA in
induction of immunosuppression in both animal and human
models, and raise the spectre of signi®cant adverse effects induced
by chronic UVA exposure, resulting in loss of protective immunity
to pathogens and loss of response UV-induced melanomas.
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